Company Information

  

Address: 275 MADISON AVENUE, 7TH FLOOR  
City: NEW YORK 
State: NY 
Zip Code: 10016 
Telephone: 646-677-3875 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and potentially commercializing targeted therapies for improved myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies are Antibody Radio-Conjugates, or ARC, that combine the targeting ability of monoclonal antibodies ("mAb") with the cell-killing ability of radioisotopes. Our ARC's have demonstrated the ability to improve access to bone marrow transplants with the potential for better outcomes, namely increased marrow engraftment and survival. Our product pipeline consists of two ARC product candidates that are currently being studied in three clinical trials. Two additional clinical trials are expected to begin patient enrollment in 2018. In each of the indications, we believe our product candidates are either first-in-class or have best-in-class potential.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-0.25NAN/E
03/2018-0.33NAN/E
12/2017-0.40NAN/E
09/2017-0.46NAN/E
06/2017-0.52NAN/E
03/2017-0.54NAN/E
12/2016-0.50NAN/E
09/2016-0.89NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.15Total Liab/Total Assets0.25
Net Inc/Total Assets-1.45Total Liab/Inv Cap0.34
Net Inc/Inv Cap-1.95Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/Equity0.00
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio3.82
Inventory TurnoverNACurrent Ratio3.82
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.57 1.88 1.34 1.86
Operating Income -4.91 -6.35 -5.21 -6.70
Interest Exp NA NA NA NA
Pretax Income -4.87 -6.31 -5.16 -6.32
Other Income 0.04 0.04 0.04 0.37
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -4.87 -6.31 -5.16 -6.32

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 21.51 26.80 17.40 20.54
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 22.08 27.65 17.84 21.21
Net Property, Plant & Equipment 0.06 0.05 0.06 0.07
Total Assets 22.58 28.14 18.34 21.72
Liabilities        
Accounts Payable 5.27 6.39 4.65 3.48
Debt in Current Liabilities 0.00 0.01 0.02 0.05
Total Current Liabilities 5.27 6.39 4.67 3.53
Long-Term Debt NA NA NA NA
Total Liabilities 5.27 6.39 4.67 3.53
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.11 0.11 0.08 0.08
Retained Earnings -174.39 -169.47 -163.15 -157.99
Treasury Stock NA NA NA NA
Total Stockholders' Equity 17.32 21.75 13.67 18.19
Total Liabilities and Stockholders' Equity 22.58 28.14 18.34 21.72

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -4.21 -5.46 -3.17 -5.87
Net Cash Provided by Investing Activities -0.02 -0.01 -0.00 -0.36
Net Cash Provided by Financing Activities -1.06 14.87 0.03 14.96

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-10.77-0.47
12/20140.00-24.69-0.90
12/20150.00-21.030.55
12/20160.00-24.32-0.50
12/20170.00-26.60-0.40
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/185010,9539.92




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.